Knut Eis

Medicine · Health Sciences

13h-index1.2kcitations61works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(18), HER2/EGFR in Cancer Research(16), Cancer therapeutics and mechanisms(6), Fibroblast Growth Factor Research(6), Cancer-related Molecular Pathways(5)

Publications61 total

Table S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S6 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Table S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S2 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Data from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Supplementary Methods 1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S7 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Table S2 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Table S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S8 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Table S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Figure S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026Open Access
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Cancer Discovery·2025· 3 citedOpen Access
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling
Cell chemical biology·2024· 9 cited
Abstract 4584: Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I and Rho-GTPase signaling
Cancer Research·2024
Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I / Rho-GTPase signaling
2023Open Access
Novel YAP1/TAZ Pathway Inhibitors Identified Through Phenotypic Screening with Potent Anti-Tumor Activity via Blockade of GGTase-I / Rho-GTPase Signaling
SSRN Electronic Journal·2023Open Access
page 1 of 4Next →

Frequent Co-authors

Franziska Siegel(20), Ulf Boemer(19), Kirstin Petersen(17), Philip Lienau(17), R.C. Hillig(16), Dominik Mumberg(16), Jérémie Mortier(15), Sven Golfier(15), Franz von Nussbaum(13), Stephan Siegel(13), Daniel Korr(13), Timothy A. Lewis(13), Volker Schulze(12), Markus Berger(11), Kristýna Kotýnková(10), H Tomono(10), Sawyer Andersen(10), D.R. Denney(10), Dominik Rüttinger(10), Matthew Meyerson(9)